A5022137528- Cancer Immunotherapy and Biomarkers
- Esophageal Cancer Research and Treatment
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Salivary Gland Tumors Diagnosis and Treatment
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Immune Cell Function and Interaction
- Head and Neck Surgical Oncology
- Cancer Genomics and Diagnostics
- Anodic Oxide Films and Nanostructures
- Sympathectomy and Hyperhidrosis Treatments
- Melanoma and MAPK Pathways
- Neuroendocrine Tumor Research Advances
- Nausea and vomiting management
- Extracellular vesicles in disease
- Esophageal and GI Pathology
- RNA and protein synthesis mechanisms
- Ear and Head Tumors
- Multiple and Secondary Primary Cancers
- Pathogenesis and Treatment of Hiccups
- Cancer Treatment and Pharmacology
- melanin and skin pigmentation
- Chromatin Remodeling and Cancer
Xinxiang Medical University
2023-2024
First Affiliated Hospital of Xinxiang Medical University
2022-2024
Shanxi Medical University
2023
PURPOSE This phase 3 trial aimed to compare the efficacy and safety of capecitabine or plus oxaliplatin (XELOX) with those fluorouracil cisplatin (PF) in definitive concurrent chemoradiotherapy (DCRT) for inoperable locally advanced esophageal squamous cell carcinoma (ESCC). METHODS Patients were randomly assigned receive two cycles capecitabine, XELOX, PF along intensity-modulated radiation therapy. each arm again consolidation chemotherapy not. The primary end points 2-year overall...
Use of chimeric antigen receptors (CARs), as an immune cell therapy, has generated excellent clinical outcomes against hematologic tumors in recent years. Among them, the CAR-NK (natural killer) therapy shown better efficacy, and less toxicity, than receptor T-cell (CAR-T) therapy. In our phase II trials, administering costimulatory converting (CCCR)-NK92 cells on advanced non-small lung cancer patients proved efficacious animal experiments. However, we observed occurrence cytokine release...
8093 Background: SCLC is characterized by a high rate of proliferation and poor prognosis, new therapies are urgently needed. B7-H3 highly expressed in SCLC. HS-20093, B7-H3-targeted antibody-drug conjugate (ADC), demonstrated antitumor activity advanced solid tumors the dose escalation part ARTEMIS-001 study (Jie Wang et al., JCO, 2023) (NCT05276609). Here, we present results on efficacy safety expansion doses patients (pts) with from phase 1a/b. Methods: consisted (1a) (1b) part. Pts were...
Background CameL phase 3 study demonstrated the superiority of camrelizumab plus chemotherapy over alone for progression-free survival in patients with previously untreated advanced non-squamous non-small-cell lung cancer (NSCLC) without EGFR / ALK alterations. Here, we present 5-year outcomes. Methods Patients were randomized (1:1) and received 4–6 cycles carboplatin pemetrexed (n=205) or (n=207) every weeks, followed by maintenance only. Crossover from group to monotherapy was permitted...
384 Background: CAP 02 study (NCT03736863) is a single-arm phase 2 to evaluate the efficacy and safety of camrelizumab plus apatinib (a VEGFR2 inhibitor) as second-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC). Cohort 1 has been published recently, which enrolled who progressed after or were intolerant first-line chemotherapy. The results showed an encouraging median overall survival (OS) 15.8 months. Here, we reported preliminary cohort 2. Methods:...
<title>Abstract</title> This case report features a patient with an invasive thymoma. The presented anterior mediastinal mass that invaded the left brachiocephalic trunk vein, resulting in formation of carcinoma thrombus right atrium-superior vena cava-left vein and internal jugular (Masaoka stage IV). No indication for surgery was assessed by surgical consultation. Following 6 cycles chemotherapy chest radiotherapy, achieved significant improvement efficacy. After follow-up 40 months,...
Cell death mechanisms are integral to the pathogenesis of breast cancer (BC), with ATP-induced cell (AICD) attracting increasing attention due its distinctive specificity and potential therapeutic applications.
Exosomal programmed cell-death ligand 1 (ePD-L1) can influence immune inhibition and dysfunction. We were dedicated to unearthing the relation between ePD-L1 in blood pathological characteristics as well PD-L1 tumor tissues. recruited 65 non-small cell lung cancer (NSCLC) patients for exosome extraction detected expression these by enzyme-linked immunosorbent assay (ELISA) method. Besides, correlation patients' was also analyzed. The of tissues tested immunohistochemistry (IHC) its with...
e16052 Background: Immunotherapy, particularly with anti-PD-1/PD-L1 antibodies, has shown therapeutic efficacy in various malignancies. Compared chemotherapy, anti-PD-1 antibody monotherapy improved the median overall survival advanced or metastatic esophageal cancer. The combination of an angiogenesis inhibitor many cancers which including purpose this study is to investigate and safety anlotinib plus PD-1 inhibitors as chemo-free therapy during treatment cancer real world setting. Methods:...
Primary submandibular gland tumors are relatively rare. Due to its low incidence and broad spectrum phenotypic, biological clinical heterogeneity types, a wide range of options have been developed treat this tumor. To date, however, efficacious standard treatment regimens lacking. Here, the authors present case patient with an advanced Histological imaging results diagnosed as stage IV adenocarcinoma multiple metastases. The was subjected systemic platinum-based chemotherapy combined...
310 Background: Compared to standard chemotherapy, immune checkpoint inhibitors monotherapy and combined with chemotherapy regimens have been shown significant benefits for patients advanced or metastatic esophageal cancer in both second-line first-line treatment, respectively. Anlotinib was an effective squamous cell carcinoma China the combination of anlotinib immunotherapy might be a promising strategy. The study aimed investigate efficacy safety plus PD-1 during treatment real world...
Abstract Background: Tislelizumab, an anti-programmed cell death protein 1 (PD-1) antibody, + chemotherapy (chemo) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) vs placebo chemo, with manageable safety profile, as first line (1L) treatment for patients (pts) advanced or metastatic esophageal squamous carcinoma (ESCC) at interim analysis of the phase 3 RATIONALE-306 study. We report data from China subgroup analysis. Methods: In this...
Abstract A randomized, open-label, parallel-controlled study was conducted to compare the efficacy of two kind three-drug Regimens containing olanzapine/dexamethasone for prevention CINV induced by hyperemetic chemotherapy. The results showed that there no significant difference in complete response rates nausea and vomiting between groups. However, anxiety, depression sleep quality patients olanzapine group were improved. It concluded antiemetic regimen "olanzapine...
Abstract Background: Our research for treating parotid adenocarcinoma was relatively slow due to its rare incidence. The consensus pulmonary metastasis from remains unclear as modern medicine is ineffective patients with distant of primary adenocarcinoma.Case presentation: A male patient presented and received three courses pembrolizumab combined chemotherapy a first-line treatment. After which, there an opportunity surgery. No tumor cells were found in postoperative pathology. achieved...
e21011 Background: EGFR exon 20 mutations are associated with acquired resistance to tyrosine kinase inhibitors (TKIs). usually not present alone, suggesting a more complex subtype of mutations. Methods: In this study, we retrospectively analyzed the different subtypes and compound mutation profiles A total 1,233 NSCLC patients’ tumors were collected detected by next-generation sequencing (NGS) from May 2020 June 2021. Results: 415 patients' harbored mutations, accounting for 33.66% entire...